{
  "paper_id": "PMC9833841",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833841/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "FIGURE 1:",
      "caption": "Summary of histological, molecular, and clinical subtypes of breast cancer. Scale bars for the images of ILC and IDC indicate 50μm lengths.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/45d68a52c580/nihms-1841001-f0001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/45d68a52c580/nihms-1841001-f0001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/45d68a52c580/nihms-1841001-f0001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/45d68a52c580/nihms-1841001-f0001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/45d68a52c580/nihms-1841001-f0001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9833841/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/45d68a52c580/nihms-1841001-f0001.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "caption": "In IDC, data suggests higher levels of all TILs, including FOXP3+ T cells. T cells in the TIME for IDCs are typically characterized by PD-1+ and LAG3+. Additionally, there are both M1-like and M2-like macrophages present. However, in ILCs, there tends to be increased levels of M2-like macrophages, lower levels of TILs, and T cells characterized by PD-1+ and TIGIT+ compared to IDCs.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/c137d6284d7c/nihms-1841001-f0003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/c137d6284d7c/nihms-1841001-f0003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/c137d6284d7c/nihms-1841001-f0003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/c137d6284d7c/nihms-1841001-f0003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/c137d6284d7c/nihms-1841001-f0003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9833841/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/c137d6284d7c/nihms-1841001-f0003.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "FIGURE 4:",
      "caption": "Summary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/98dc41fc6835/nihms-1841001-f0004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/98dc41fc6835/nihms-1841001-f0004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/98dc41fc6835/nihms-1841001-f0004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/98dc41fc6835/nihms-1841001-f0004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/98dc41fc6835/nihms-1841001-f0004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9833841/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7de9/9833841/98dc41fc6835/nihms-1841001-f0004.jpg"
    }
  },
  "claims": [
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "FIGURE 1:\n\nOpen in a new tab\nSummary of histological, molecular, and clinical subtypes of breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In this review, we aim to compare and contrast the immune response across the different molecular and histological subtypes of early-stage breast cancer, including HR+ (Luminal A and Luminal B), HER2+, and TNBC, as well as between HR+ IDC and HR+ ILC (given the majority of ILC diagnoses are HR+) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "FIGURE 2:\n\nOpen in a new tab\n(A) Comparison of unique tumor-intrinsic features of the breast cancer subtypes.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Based on the gene modules, Luminal A cells were enriched in pathways related to estrogen response, but also enriched with respect to TNF signaling through NF-κB, hypoxia, and apoptosis, suggesting a role for secretory products interacting with the immune system in the HR+ subtype (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the cancer cell-intrinsic factors in HR+, HER2+, and TNBCs are one component in the varying interactions between tumor and non-tumor cells in the TIME (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Taken together, the TIME varies markedly between the three major molecular breast cancer subtypes (131) (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "FIGURE 3: Key differences in the TIME between ER+ ILC and ER+ IDC.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The vast majority of these tumors are HR+ and fall into the Luminal A PAM50 subtype; distinct from patients with IDC, patients with ILC are more often diagnosed at older ages, typically have larger, multifocal tumors, and may have a unique propensity for late tumor recurrences (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "ILCs can be additionally categorized into a “reactive” breast cancer subtype, which is defined by a high intratumoral stromal component without many infiltrating immune cells (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, ILC have a distinct interaction with the immune system given the enrichment of stromal content (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "FIGURE 4:\n\nOpen in a new tab\nSummary of key questions to guide the future of immune system investigation across breast cancer molecular and histological subtypes.In conclusion, to aid the interrogation of the aspects of TIME stated above, recently developed sophisticated approaches for sequencing, imaging, and in vivo syngeneic animal studies that are currently under-utilized in subtype-specific breast cancer research must be leveraged.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "For further rational design of immunotherapy with maximal benefit, we must thoroughly characterize the TIME of the different molecular and histological breast cancer subtypes to understand and address a series of outstanding questions (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 120,
    "images_downloaded": 3,
    "tables_filtered": 6
  }
}